Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is...

Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March...